Abstracts Archive - Page 2189 of 2607 - ACR Meeting Abstracts

Abstract Number: 667 • 2014 ACR/ARHP Annual Meeting
24-Month Outcomes Associated with Belimumab in Patients with Systemic Lupus Erythematosus in Clinical Practice Settings
Christopher E. Collins¹, Hong Kan², Maria Dall'era³, Cynthia Macahilig⁴, Ramesh Pappu², Charles T. Molta⁵ and Volker Koscielny⁶, ¹MedStar Washington Hospital Center, Washington, DC, ²GlaxoSmithKline, Research Triangle Park, NC, ³UCSF, San Francisco, CA, ⁴Medical Data Analytics, Parsippany, NJ, ⁵GlaxoSmithKline, Philadelphia, PA, ⁶Medical Department, GlaxoSmithKline, Brentford, United Kingdom
Background/Purpose: The clinical efficacy of belimumab in patients with systemic lupus erythematosus (SLE) has been demonstrated in large randomized clinical trials. We examined clinical outcomes…
Abstract Number: 668 • 2014 ACR/ARHP Annual Meeting
Evolution of Patients with Systemic Lupus Erythematous Treated with Belimumab in Clinical Practice Settings
Josefina Cortes¹, Carlos Marras², Jose Luis Andreu³, Jaime Calvo-Alen⁴, Angel M. Garcia-Aparicio⁵, Elvira Diez Alvarez⁶, Carlos Coronell⁷, Elena Morejon⁷, Alessandra Perna⁸, Volker Koscielny⁸ and Josep Ordi-Ros¹, ¹Internal Medicine, Vall d´Hebron Hospital, Barcelona, Spain, ²Rheumatology, Virgen de la Arrixaca Hospital, Murcia, Spain, ³Rheumatology, Puerta de Hierro Universitary Hospital, Madrid, Spain, ⁴Rheumatology Division, Sierrallana Hospital, Torrelavega, Spain, ⁵Rheumatology, Virgen de la Salud Hospital, Toledo, Spain, ⁶Rheumatology, Leon Hospital, Leon, Spain, ⁷Medical Department, GlaxoSmithKline, Madrid, Spain, ⁸Medical Department, GlaxoSmithKline, Brentford, United Kingdom
Background/Purpose After the approval of belimumab for patients with systemic lupus erythematosus (SLE), the objective of this study is to describe the clinical outcomes associated…
Abstract Number: 666 • 2014 ACR/ARHP Annual Meeting
Approach to Discriminate Treatment Impact in Both Moderate and Severe SLE: The Atacicept Phase IIb Trial Design
Joan T. Merrill¹, Yong Li², Stephen D. Wax³ and Christopher Tehlirian⁴, ¹Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²R&D Global BioStatistics, EMD Serono, Billerica, MA, ³Global Clinical Development Center - Immunology, EMD Serono Inc, Rockland, MA, ⁴EMD Serono, Rockland, MA
Background/Purpose Increases in background treatment in SLE trials lead to high placebo group responses in patients with moderate but not those with high disease activity…
Abstract Number: 665 • 2014 ACR/ARHP Annual Meeting
Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus
Jing He¹, Xia Zhang², Xiaolin Sun³, Jianping Guo³, Yunbo Wei⁴, Zhaohua Hou⁴, Yu Di⁵ and Zhanguo Li³, ¹Department of Rheumatology & Immunology, Peking University People's Hospital, Beijing, China, ²Department of Rheumatology & immunology, Peking University People's Hospital, Beijing, China, ³Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ⁴Immunology for Environment and Health, Shandong Analysis and Test Center, Shandong Academy of Science, Shandong, China, ⁵Molecular Immunomodulation Laboratory, Monash University, Clayton, Austria
Background/Purpose Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by loss of tolerance to nuclear self-antigens, production of pathogenic autoantibodies and damage tomultiple organs.…
Abstract Number: 664 • 2014 ACR/ARHP Annual Meeting
The Pathogenesis of Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Brain Intrinsic Factors
Ariel Stock¹, Jing Wen², Jessica Doerner² and Chaim Putterman³, ¹Albert Einstein College of Medicine, Bronx, NY, ²Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ³Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Neuropsychiatric disease is a common manifestation of systemic lupus erythematosus (SLE). Frequent presentations include depression, anxiety, memory loss and cognitive decline. The pathogenesis of…
Abstract Number: 663 • 2014 ACR/ARHP Annual Meeting
STAT3 Inhibition Delays the Onset of Lupus Nephritis in MRL/Lpr Mice
Linsday Edwards¹ and Vasileios C. Kyttaris², ¹Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, ²Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose The transcription factor Signal transducer and activator of transcription (STAT) 3 is overexpressed and aberrantly activated in patients with SLE as well as lupus-prone…
Abstract Number: 662 • 2014 ACR/ARHP Annual Meeting
Interferon Regulatory Factor-5 Promotes Disease in the MRL/Lpr Mouse Model of Lupus
Amanda Watkins¹, Ramon Bonegio², Guneet Kochar¹, Gabriella Wilson¹, Bari Laskow¹, Christophe Richez¹, Ian Rifkin¹ and Kei Yasuda³, ¹Boston University School of Medicine, Boston, MA, ²Renal, Boston University School of Medicine, Boston, MA, ³Medicine, Boston University School of Medicine, Boston, MA
Background/Purpose Interferon regulatory factor 5 (IRF5) polymorphisms are strongly associated with an increased risk of developing Systemic Lupus Erythematosus (SLE). SLE is caused, in part,…
Abstract Number: 661 • 2014 ACR/ARHP Annual Meeting
Dysfunction of Glycosphingolipid Metabolism in Lupus Nephritis
Thirumagal Thiyagarajan¹, Leah Siskind², Jim Oates³, Richard Drake⁴ and Tamara K. Nowling⁵, ¹Medicine, Medical University of South Carolina, Charleston, SC, ²University of Louisville, Louisville, KY, ³Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ⁴Pharmacology, Medical University of South Carolina, Charleston, SC, ⁵Medicine/Rheumatology, Medical University of South Carolina and Ralph H. Johnson VA Medical Center, Charleston, SC
Background/Purpose: Lupus is a chronic autoimmune disease characterized by autoantibody production and aberrant activation and proliferation of lymphocytes. Subsequent deposition of immune complexes in target…
Abstract Number: 660 • 2014 ACR/ARHP Annual Meeting
Microthrombotic Renal Vascular Lesions Are Associated to Increased Renal Inflammatory Infiltration in a Mouse Model of Lupus Nephritis
María Galindo¹, Elena Gonzalo-Gil², Oscar Toldos³, Carmen García-Herrero², Alicia Usategui¹, Sonia Pérez-Yagüe⁴, Gabriel Criado⁵, Domingo F. Barber⁴ and Jose L. Pablos¹, ¹Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ²Department of Rheumatology, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ³Servicio de Anatomia Patologica, Hospital 12 de Octubre, Madrid, Spain, ⁴Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain, ⁵Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain
Background/Purpose In patients with lupus nephritis (LN), acute renal vascular and atherosclerotic lesions correlate with the degree of inflammation regardless the presence of antiphospholipid antibodies.…
Abstract Number: 658 • 2014 ACR/ARHP Annual Meeting
17β Estradiol Regulates VCAM-1 Expression during Glomerulonephritis
Neelakshi Jog¹ and Roberto Caricchio², ¹Rheumatology, Temple University, Philadelphia, PA, ²Medicine/Rheumatology, Temple University, Philadelphia, PA
Background/Purpose The immunomodulating roles of estrogens are not completely understood. Although 17β estradiol (E2) has been shown to promote systemic autoimmunity, it has also been…
Abstract Number: 657 • 2014 ACR/ARHP Annual Meeting
Distinct Contributions of C1q and C3 in Preventing Immunogenicity of Apoptotic Cells in Lupus
Clayton Sontheimer¹, Yenly Nguyen², Keith B. Elkon³ and YuFeng Peng³, ¹Pediatric Rheumatology, University of Washington, Seattle, WA, ²University of Washington, Seattle, WA, ³Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Defective clearance of apoptotic cells (AC) and complement deficiency are important contributors to the pathogenesis of systemic lupus. Dead (sunburn) cells and complement…
Abstract Number: 656 • 2014 ACR/ARHP Annual Meeting
Breach of B Cell Tolerance in New Zealand Black Chromosome 1 Congenic Mice
Kieran Manion^1,2, Nan-Hua Chang³, Yuriy Baglaenko^1,2 and Joan Wither^1,3, ¹Immunology, University of Toronto, Toronto, ON, Canada, ²Genetics and Development, Toronto Western Research Institute, University Health Network, Toronto, ON, Canada, ³Genetics and Development, Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Mapping studies in the lupus-prone New Zealand Black (NZB) mouse strain identified an interval from 170.8-181 Mb on chromosome 1 sufficient to induce B…
Abstract Number: 655 • 2014 ACR/ARHP Annual Meeting
Hydroxycholorquine Is Cardioprotective in an In Vivo Rat Model of Myocardial Ischaemic Reperfusion Injury
Lauren Bourke^1,2, Valerie Taylor³, James McCormick⁴, Charis Pericelous¹, John Franklin¹, Daniel Stuckey³, Mark Lythgoe⁵, Anastasis Stephanou⁶ and Yiannis Ioannou^2,7, ¹Centre for Rheumatology Research, University College London, London, United Kingdom, ²Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ³Centre for Advanced Biomedical Imaging (CABI), University College London, London, United Kingdom, ⁴Clinical & Molecular Genetics Unit, University College London, London, United Kingdom, ⁵Centre for Advanced Biomedical Imaging, Centre for Advanced Biomedical Imaging (CABI), University College London, London, United Kingdom, ⁶Medical and Molecular Biology Unit (MMBU), University College London, London, United Kingdom, ⁷Centre for Rheumatology Research, University College Hospital London, London, United Kingdom
Background/Purpose A significant amount of myocardial damage during a myocardial infarction (MI) occurs during the reperfusion stage which is known as ischaemic reperfusion (I/R) injury…
Abstract Number: 654 • 2014 ACR/ARHP Annual Meeting
Type I Interferon Induces the Depletion and Dysfunction of Endothelial Progenitor Cells in Gld. ApoE-/- C57BL/6 Mice
Linyu Geng¹, Shiying Wang¹, Xuebing Feng² and Lingyun Sun², ¹The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose To study whether the accelerated atherosclerosis in SLE is mediated by type I interferon (IFN-I) through the regulation of endothelial progenitor cells (EPCs) in…
Abstract Number: 653 • 2014 ACR/ARHP Annual Meeting
Dermal Injury Promotes Nephritis Flare in Lupus-Prone NZM2328 Mice
Kaitlyn Clark¹, Tamra J. Reed¹, Jeffrey B. Hodgin² and J. Michelle Kahlenberg³, ¹Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ²Department of Pathology, University of Michigan, Ann Arbor, MI, ³Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic lupus erythematosus is an autoimmune disease with pleotropic manifestations, including severe skin disease, hematologic abnormalities and nephritis. Clinically, lupus is characterized by episodes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].